Chuluunbat Tsengelmaa, Chan R V Paul, Wang Nan-Kai, Lien Reyin, Chen Yen-Po, Chao An-Ning, Chen Kuan-Jen, Chen Tun-Lu, Hwang Yih-Shiou, Lai Chi-Chun, Wu Wei-Chi
Ophthalmic Surg Lasers Imaging Retina. 2016 Dec 1;47(12):1095-1105. doi: 10.3928/23258160-20161130-03.
To evaluate the surgical outcome of type 1 retinopathy of prematurity (ROP) after intravitreal ranibizumab (IVR) (Lucentis; Genentech, South San Francisco, CA) treatment.
This was a prospective case series. Premature infants with treatment-requiring ROP who received IVR injections from 2013 to 2015 were included.
Twenty-two eyes of 12 children were included in the study. Complete resolution of ROP after a single IVR was noted in 73% of eyes. Retreatment was needed in 27% of eyes due to nonresponse to IVR (18%) or recurrence of ROP (9%). After that, all treated eyes (100%) demonstrated regressed ROP with attached retina. The median visual acuity was 0.3 LogMAR (range: 0 LogMAR to 0.8 LogMAR) with a mean follow-up of 25.2 months ± 6.8 months.
IVR is effective and well-tolerated for patients with treatment-requiring ROP. However, nonresponse to IVR or recurrence of ROP after IVR was noted in 27% of treated eyes and required additional treatment. [Ophthalmic Surg Lasers Imaging Retina. 2016;47:1095-1105.].
评估玻璃体内注射雷珠单抗（IVR，商品名：Lucentis；基因泰克公司，美国加利福尼亚州南旧金山）治疗1型早产儿视网膜病变（ROP）的手术效果。
这是一项前瞻性病例系列研究。纳入2013年至2015年接受IVR注射治疗的需要治疗的ROP早产儿。
12名儿童的22只眼纳入研究。73%的患眼在单次IVR治疗后ROP完全消退。27%的患眼因对IVR无反应（18%）或ROP复发（9%）需要再次治疗。此后，所有接受治疗的患眼（100%）ROP均消退，视网膜复位。平均随访25.2个月±6.8个月，平均视力为0.3 LogMAR（范围：0 LogMAR至0.8 LogMAR）。
IVR治疗需要治疗的ROP患者有效且耐受性良好。然而，27%的患眼对IVR无反应或IVR治疗后ROP复发，需要进一步治疗。[《眼科手术、激光与视网膜影像》。2016；47：1095 - 1105。]
